ReShape Lifesciences Inc.

NASDAQ: RSLS · Real-Time Price · USD
4.20
-0.05 (-1.18%)
At close: Jun 06, 2025, 3:59 PM
4.01
-4.52%
After-hours: Jun 06, 2025, 05:56 PM EDT

Company Description

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally.

The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.

It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus.

In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement.

The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017.

ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

ReShape Lifesciences Inc.
ReShape Lifesciences Inc. logo
Country United States
IPO Date Oct 6, 2016
Industry Medical - Devices
Sector Healthcare
Employees 17
CEO Paul F. Hickey

Contact Details

Address:
1001 Calle Amanecer
San Clemente, California
United States
Website https://www.reshapelifesciences.com

Stock Details

Ticker Symbol RSLS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001427570
CUSIP Number 76090R408
ISIN Number US76090R4083
Employer ID 00-0000000
SIC Code 3841

Key Executives

Name Position
Paul F. Hickey Chief Executive Officer, President & Director
Thomas Stankovich Senior Vice President & Chief Financial Officer
Al Diaz Vice President of Operations and R&D
Dan W. Gladney Executive Chair
Dr. Dov Gal D.V.M., M.B.A. Vice President of Regulatory Clinical Quality & Compliance Officer
Naqeeb A. Ansari Senior Vice President of Global Commercial Operations

Latest SEC Filings

Date Type Title
May 30, 2025 424B5 Filing
May 30, 2025 8-K Current Report
May 30, 2025 8-K Current Report
May 28, 2025 8-K Current Report
May 20, 2025 10-Q Quarterly Report
May 15, 2025 NT 10-Q Filing
May 14, 2025 SCHEDULE 13G Filing
May 14, 2025 S-4/A [Amend] Filing
May 12, 2025 SCHEDULE 13G/A [Amend] Filing
May 09, 2025 S-3 Filing